SLC19A2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P07601(SLC19A2 Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

The solute carrier family 19 member 2 (SLC19A2) gene encodes a high-affinity thiamine (vitamin B1) transporter protein, essential for cellular uptake of thiamine, a cofactor critical for carbohydrate metabolism and neurological function. Mutations in SLC19A2 are linked to thiamine-responsive megaloblastic anemia (TRMA), a rare autosomal recessive disorder characterized by anemia, diabetes mellitus, and sensorineural hearing loss. SLC19A2 is predominantly expressed in tissues with high metabolic demands, including the intestines, placenta, and bone marrow.

Antibodies targeting SLC19A2 are vital tools for studying its expression, localization, and functional roles. They enable detection of the protein via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the investigation of thiamine transport mechanisms and disease-related dysregulation. In research, these antibodies help validate SLC19A2 knockout models or assess protein levels in TRMA patients, where loss-of-function mutations impair thiamine absorption. Clinically, they assist in diagnosing TRMA by confirming reduced or absent SLC19A2 expression in affected tissues.

However, antibody specificity must be rigorously validated, as cross-reactivity with related transporters (e.g., SLC19A1 or SLC19A3) can yield misleading results. Commercial SLC19A2 antibodies vary in performance across experimental conditions, emphasizing the need for optimization. Despite challenges, these reagents remain crucial for unraveling the pathophysiology of TRMA and exploring therapeutic strategies to restore thiamine transport in deficient cells.